Health Canada approves Lipocine-partnered TLANDO for testosterone replacement therapy

PUBT · 1d ago
Health Canada approves Lipocine-partnered TLANDO for testosterone replacement therapy
  • Health Canada cleared TLANDO capsules for testosterone replacement therapy in adult men with hypogonadism.
  • Verity Pharma holds exclusive North American commercial rights; it targets a Canadian launch by end-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-046060), on October 07, 2026, and is solely responsible for the information contained therein.